Currently, there are 97.25M common shares owned by the public and among those 96.27M shares have been available to trade.
The company’s stock has a 5-day price change of 18.88% and -5.44% over the past three months. ONC shares are trading 13.74% year to date (YTD), with the 12-month market performance up to 25.20% higher. It has a 12-month low price of $126.97 and touched a high of $248.16 over the same period. ONC has an average intraday trading volume of 360.02K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 13.58%, 9.76%, and 16.50% respectively.
Institutional ownership of BeiGene Ltd ADR (NASDAQ: ONC) shares accounts for 44.07% of the company’s 97.25M shares outstanding.
It has a market capitalization of $20.53B and a beta (3y monthly) value of 0.62. The earnings-per-share (ttm) stands at -$8.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.90% over the week and 3.14% over the month.
Earnings per share for the fiscal year are expected to increase by 36.82%, and 93.68% over the next financial year.
Looking at the support for the ONC, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on December 03, 2024, with the firm’s price target at $300. JMP Securities coverage for the BeiGene Ltd ADR (ONC) stock in a research note released on September 18, 2024 offered a Mkt Outperform rating with a price target of $288. JP Morgan was of a view on February 06, 2024 that the stock is Overweight, while Macquarie gave the stock Outperform rating on September 12, 2023, issuing a price target of $259. Jefferies on their part issued Buy rating on August 17, 2023.
